Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Amicus Therapeutics
Amicus Therapeutics
Activities:
Research & Development
Finance
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Catalent wins CDMO contract with Amicus Therapeutics
The US biotech company has chosen Paragon Gene Therapy development and manufacturing capability for lysosomal disorder programmes
Manufacturing
Amicus chooses Thermo Fisher for gene therapy CDMO services
Collaboration will focus on the rare genetic cause of Batten disease
Design & Build
Amicus builds global R&D centre for gene therapy in the US
Located in Philadelphia, the new 75,000 sqft facility will be completed in the second half of 2019
Manufacturing
WuXi Biologics inks commercial agreement with Amicus
Chinese biotech company has become exclusive drug substance manufacturing partner and key commercial drug product supplier for Pompe biologic ATB200
Research & Development
Drug licensing deals in 2010
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development
GSK and Amicus Therapeutics sign exclusive agreement
To develop and commercialise Amigal for Fabry disease
Subscribe now